Disease · HP_0025502

Overweight

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Overweight. Diseases, record HP_0025502. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0025502

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Overweight
Open Targets ID: HP_0025502
Highest stage of its drugs: Approval, for 5 of its 77 drugs, from EMA Human Drugs

Source Open Targets

Drugs77

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SEMAGLUTIDE	CHEMBL2108724	Protein	Approval	EMA Human Drugs	34	33	32	Drugs and targets
TIRZEPATIDE	CHEMBL4297839	Protein	Approval	EMA Human Drugs	24	23	23	Drugs and targets
LIRAGLUTIDE	CHEMBL4084119	Protein	Approval	EMA Human Drugs	15	13	13	Drugs and targets
BUPROPION	CHEMBL894	Small molecule	Approval	EMA Human Drugs	5	4	4	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Approval	EMA Human Drugs	5	4	4	Drugs and targets
CAGRILINTIDE	CHEMBL4802169	Protein	Phase 3	ClinicalTrials.gov	14	14	13	Drugs and targets
ELORALINTIDE	CHEMBL6068462	Protein	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
ORFORGLIPRON	CHEMBL4446782	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
MAZDUTIDE	CHEMBL5095358	Protein	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
SURVODUTIDE	CHEMBL5314776	Protein	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 77

See all 77 drugs

Targets118

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GLP1R	Glucagon-like peptide 1 receptor	6	Glucagon-like peptide 1 receptor agonist	Approval	https://conductscience.org/library/genes/2740	Drugs and targets
GCGR	Glucagon receptor	4	Glucagon receptor agonist	Phase 3	https://conductscience.org/library/genes/2642	Drugs and targets
CNR1	Cannabinoid receptor 1	3	Cannabinoid CB1 receptor antagonist; Cannabinoid CB1 receptor inverse agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/1268	Drugs and targets
SLC6A2	Monoamine transporter	3	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/56901	Drugs and targets
GIPR	Gastric inhibitory polypeptide receptor	2	Gastric inhibitory polypeptide receptor agonist	Approval	https://conductscience.org/library/genes/2696	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	2	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/2820	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	2	Serotonin 2c (5-HT2c) receptor agonist	Phase 3	https://conductscience.org/library/genes/3358	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4535	Drugs and targets

1 to 10 of 118

See all 118 targets

Trials174

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00603902	BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management	Phase 3	4,008	2013-02-07	Obesity	LORCASERIN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00395135	BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management	Phase 3	3,182	2013-02-07	Obesity	LORCASERIN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT03548935	STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	Phase 3	1,961	2021-08-11	Metabolism and Nutrition Disorder, Overweight or Obesity	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT03548987	Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	Phase 3	902	2021-03-15	Metabolism and Nutrition Disorder, Obesity	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT01272232	Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes	Phase 3	846	2015-02-09	Metabolism and Nutrition Disorder, Obesity	LIRAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT00796367	A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)	Phase 3	676	2012-08-31	Obesity	PHENTERMINE, TOPIRAMATE	Its record names the disease	ClinicalTrials.gov
NCT00603291	BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus	Phase 3	604	2013-02-07	Obesity	LORCASERIN	Its record names the disease	ClinicalTrials.gov
NCT05616013	Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese	Phase 2	507	2025-07-18	Obesity, Obese, Overweight or Obesity	BIMAGRUMAB, SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT02963922	Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin	Phase 3	396	2019-11-27	Metabolism and Nutrition Disorder, Obesity	LIRAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT04667377	A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight	Phase 2	387	2023-11-02	Obesity	SURVODUTIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 174

See all 174 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sema 2.4 mg vs Placebo: deaths from any cause	1 of 1,306	1 of 655	1,961	NCT03548935	Trial comparisons
Sema 2.4 mg vs Placebo: serious adverse events	128 of 1,306	42 of 655	1,961	NCT03548935	Trial comparisons
Liraglutide 3.0 mg vs Placebo: deaths from any cause	0 of 195	0 of 197	392	NCT02963922	Trial comparisons
Liraglutide 3.0 mg vs Placebo: serious adverse events	16 of 195	19 of 197	392	NCT02963922	Trial comparisons
Group A (Exenatide) vs Group B (Placebo): Number of Participants With Hypoglycemic Events During the Study	33 of 96	30 of 98	194	NCT00375492	Trial comparisons
Arm 1 vs Arm 2: serious adverse events	1 of 72	2 of 74	146	NCT00108524	Trial comparisons
Metformin Plus Weight Reduction Counseling vs Placebo Plus Weight Reduction Counseling: serious adverse events	0 of 53	0 of 47	100	NCT00005669	Trial comparisons
Active Drug vs Placebo: deaths from any cause	0 of 29	0 of 31	60	NCT03158805	Trial comparisons
Active Drug vs Placebo: serious adverse events	0 of 29	2 of 31	60	NCT03158805	Trial comparisons
SLOW-BWL vs FAST-BWL: deaths from any cause	0 of 38	0 of 15	53	NCT04499950	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials112

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40691810	RESULT	1	PubMed
36514273	RESULT	1	PubMed
33859430	RESULT	1	PubMed
33755728	RESULT	1	PubMed
33567185	RESULT	1	PubMed
32714562	RESULT	1	PubMed
32413333	RESULT	1	PubMed
32139381	RESULT	1	PubMed
30503034	RESULT	1	PubMed
28950422	RESULT	1	PubMed

1 to 10 of 112

See all 112 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0025502

GET https://conductscience.org/api/diseases/v1/HP_0025502/drugs?page=2

API reference For AI assistants